[Spectrum of therapeutic efficacy and safety of Lorafen (lorazepam) use for anxiety disorders].
Presented here, are the results of 4-weeks lorafen monotherapy in 31 in-patients of psychiatric and cardio-surgical clinics divided, respectively, into 2 groups: 16 patients with chronic anxiety disorders and 15--with acute developed before an coronary artery bypass surgery in ischemic heart disease. A dynamics of the patients' state was evaluated with Hamilton Rating Scale for Anxiety and the Hospital Anxiety and Depression Scale. Lorafen proved to be highly effective, with percentage of responders being about 77% (24 patients out of 31). Therapeutically effective dosage was 3.7 +/- 1.1 mg daily for chronic anxiety disorders and 2.1 +/- 0.6 mg--for situation-induced anxiety. Lorafen was shown to be tolerable and safety.
Ivanov
S V
SV
Il'ina
N A
NA
Burlakov
A V
AV
D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index
D014151:Anti-Anxiety Agents; D008140:Lorazepam